Novartis Will Appeal European Committee Recommendation Against Zelnorm Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
European Medicines Agency’s drug review committee agreed that tegaserod may not provide relief of irritable bowel syndrome in the standard setting.
You may also be interested in...
Novartis To Seek Licensing Partner For Pitavastatin
The firm is terminating development of its lipid-lowering agent pitavastatin after disappointing Phase II trial results.
Novartis To Seek Licensing Partner For Pitavastatin
The firm is terminating development of its lipid-lowering agent pitavastatin after disappointing Phase II trial results.
Novartis' Zelnorm Approved For Chronic Constipation Without Gender Restrictions
FDA approves the supplemental indication despite an advisory committee recommendation that tegaserod use be limited to women. The agency follows the committee's recommendation on use only in individuals under age 65.